

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

**PROPOSED APPOINTMENT OF SUPERVISOR
AND
SUPPLEMENTAL ANNOUNCEMENT IN RELATION
TO THE ANNUAL REPORTS**

Reference is made to the announcement of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”) dated May 11, 2025. According to the Articles of Association of the Company, the Company Law of the People's Republic of China and applicable laws and regulations, the board (the “**Board of Supervisors**”) of supervisors (the “**Supervisor(s)**”) of the Company proposes the appointment of Ms. Wang Yong (王泳) (“**Ms. Wang**”) as a Supervisor and the chairman of the second session of the Board of Supervisors.

The above proposed appointments of the supervisor are subject to the approval of the shareholders of the Company (the “**Shareholder(s)**”) by way of ordinary resolutions at the shareholder's general meeting.

BACKGROUND OF THE CANDIDATE FOR SUPERVISOR

Ms. Wang Yong

Wang Yong, female, aged 52, Chinese. Ms. Wang joined the Company's controlling shareholder, Lepu Medical Technology (Beijing) Co., Ltd.* (樂普(北京)醫療器械股份有限公司) (“**Lepu Medical**”) (a company listed on the ChiNext Board of the Shenzhen Stock Exchange, stock code: 300003) in March 2007 and has served as the financial controller since then. She was appointed by Lepu Medical as a deputy general manager in April 2017, and has served as the senior deputy general manager of Lepu Medical since April 2021.

Ms. Wang has served as the chairman of the board of supervisors of Sichuan Rekind Medtec., Inc. (四川睿健醫療科技股份有限公司) (a company listed on the National Equities Exchange and Quotations, stock code: 874652) since March 2016; a director of Shanghai Lepu Yunzhi Technology Co., Ltd.* (上海樂普雲智科技股份有限公司) since August 2019; a director of Waterstone Pharmaceuticals (Wuhan) Co., Ltd. (中美華世通生物醫藥科技(武漢)股份有限公司) (a company listed on the National Equities Exchange and Quotations, stock code: 873938) since June 2022; a director of Lepu (Hong Kong) Co., Limited since June 2022; and a director of Shanxi Tiansheng Pharmaceutical CO., LTD. (山西天生製藥有限責任公司) since October 2022.

Ms. Wang worked in the audit department of the Beijing Branch of PricewaterhouseCoopers Zhong Tian LLP from July 1996 to January 2007 in the following positions respectively: an assistant auditor from July 1996 to June 1998; a senior auditor from July 1998 to June 2001; an audit manager from July 2001 to June 2004; and a senior audit manager from July 2004 to January 2007.

Ms. Wang graduated from Beijing University of Technology with a Bachelor's degree in Management Engineering in July 1996 and obtained the professional qualification of Certified Public Accountant in 2001.

Save as disclosed above, Ms. Wang did not hold any position in any listed company in the past three years.

Save as disclosed in this announcement, Ms. Wang has no relationship with any directors, supervisors, members of the senior management or substantial or controlling shareholders of the Company. As at the date of this announcement, Ms. Wang is interested in 147,221 shares of the Company through an employee stock ownership platform of Lepu Medical, representing approximately 0.04% of the issued share capital of the Company. She is also interested in 191,700 shares of Lepu Medical as a beneficial owner, representing approximately 0.01% of the issued share capital of Lepu Medical and 383,955 shares of Beijing Lepu Diagnosis Technology Co., Ltd.[#] (北京樂普診斷科技股份有限公司), a subsidiary of Lepu Medical, through an employee stock ownership platform of Lepu Medical, representing approximately 0.10% of the issued share capital of Beijing Lepu Diagnosis Technology Co., Ltd. Save as disclosed in this announcement, Ms. Wang does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Upon approval of Ms. Wang's appointment by the Shareholders, Ms. Wang will enter into a service contract with the Company till the expiry of the tenure of the second session of the Board of Supervisor commencing from the date of approval of the appointment. Pursuant to the Articles of Association of the Company, Ms. Wang shall be elected and appointed at a shareholder's general meeting of the Company and may be re-elected and re-appointed at a shareholder's general meeting of the Company.

Ms. Wang will not receive remuneration as a shareholder representative Supervisor from the Company.

Save for disclosed above, there is no any other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and the Company is not aware of any other matters that need to be brought to the attention of the Shareholders.

GENERAL

The proposed appointment of the Supervisor are subject to the approval of the Shareholders by way of ordinary resolutions at the shareholder's general meeting of the Company. A circular containing, among other matters, details of the above proposed appointment and a notice of the shareholder's general meeting will be despatched to the Shareholders as soon as practicable.

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORTS

References are made to the annual report for the year 2022 dated April 25, 2023, the annual report for the year 2023 dated April 19, 2024, and the annual report for the year 2024 dated April 17, 2025 (collectively, the “**Annual Reports**”) of the Company, the Company hereby provides the following additional information. The total compensation paid to all supervisors for the years ended December 31, 2022, to December 31, 2024, respectively, is nil, which includes (i) fees for financial years, (ii) basic salaries, housing allowances and benefits in kind, and (iii) bonuses paid or payable.

The above additional information supplements, and should be read in conjunction with, the Annual Reports. The above additional information does not affect other information contained in the Annual Reports and, save as disclosed in this announcement, the remaining contents of the Annual Reports remain unchanged.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People’s Republic of China
July 18, 2025

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director, Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name “LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.”.*

For identification purposes only